-Reuters Citing Conference Call
Mizuho Bolsters Price Target By 55% On This Migraine Stock
Mizuho Securities assumes coverage of Axsome Therapeutics Inc (NASDAQ:AXSM), with a Buy rating and a price target of $76, representing a 25%…
Related Posts
Instagram Rolls Out Improved Web Interface — But iPad App Still Not In Pipeline
Meta Platforms Inc.'s (NASDAQ: META) Instagram has updated its web interface but has no immediate plans to build a dedicated app for Apple Inc.'s (NASDAQ:
Investor Sentiment Declines After July’s Producer Price Index
The CNN Money Fear and Greed index showed a decline in overall sentiment among U.S. investors on Friday.
The Nasdaq Composite closed lower on Friday, recording its second straight losing week this year. However, the Dow Jones gained by more than 100 points during the session.
BMO Downgrades Gold Fields; Reliance Steel Acquires Cooksey Iron; Law Firm Probes Contango ORE; US Steel Shares Q4, Yearly Results
Top Stories for Feb. 2, 2024:
1. BMO Capital analyst Andrew Kaip downgraded Gold Fields Limited (NYSE: GFI) from Market Perform to Underperform and lowered his price target from $14 to $12.